Showing 35,225 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

Child developmental issues

Efavirenz, but not dolutegravir, linked to neurological problems in children

News
11 October 2018
Elimination of hepatitis C

Hepatitis C elimination in people living with HIV in the UK is feasible by 2021, British HIV Association says

News
10 October 2018
Hepatitis C symptoms & diagnosis

Too Few Teens and Youth Adults Using Opioids Are Screened for Hepatitis C and HIV, New Study Finds

Editor's pick
The Body PRO
10 October 2018
Prisoners

Retention in HIV care drops after release from incarceration

Editor's pick
EurekAlert (press release)
10 October 2018
TB transmission & prevention

TB vaccine halves risk of disease in people with latent TB

News
10 October 2018

HIV update - 10th October 2018

October 2018
Palliative care

How the myth about opioids and chronic pain affects people living with HIV

Editor's pick
BETA blog
9 October 2018
New & experimental HIV treatments

Long-acting injectable implant shows promise for HIV treatment and prevention

Editor's pick
University of North Carolina
9 October 2018
HIV in the arts & media

Aids activists Gran Fury bring their rage to the UK in new show

Editor's pick
The Art Newspaper
9 October 2018
Hepatitis C treatment

Anti-virals cure up to 98% of hepatitis C patients since 2014

Editor's pick
Irish Times
9 October 2018
PrEP

Study reveals racial differences in HIV prevention method use

Editor's pick
Yale Daily News (blog)
9 October 2018
Pregnancy and vertical transmission

What you need to know about SA's historic liver transplant from an HIV-positive donor

Editor's pick
Bhekisisa
9 October 2018
PrEP science

Another rare PrEP failure reported in San Francisco

News
9 October 2018
UK health services

New report: HIV and Integrated Care – Can STPs deliver?

Editor's pick
NAT
9 October 2018
New & experimental HIV treatments

Doravirine combination works well as a switch option

News
8 October 2018
Activism & civil society

A Global Health Evangelist Is Shocked To Hear He's A 'Genius'

Editor's pick
NPR
8 October 2018
Money

The Gay Men Who Have Lived for Years With Someone Waiting on Their Death

Editor's pick
The Atlantic
8 October 2018
PrEP

HIV prevention drug PrEP to be evaluated for State funding

Editor's pick
Irish Times
8 October 2018
New & experimental HIV treatments

Dual-antibody combination therapy produces three to seven months of viral suppression without pills

News
8 October 2018
PrEP science

First U.S. Failure of Truvada as PrEP Is Reported at IDWeek

Editor's pick
The Body Pro
7 October 2018
Pregnancy and vertical transmission

HIV stigma blocks efforts to prevent mother-to-child transmission in India

Editor's pick
AVERT
5 October 2018
Changing treatment

Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens

Editor's pick
Merck press release
5 October 2018
Changing treatment

Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1

Editor's pick
Janssen press release
5 October 2018
Child developmental issues

Efavirenz in HIV-positive pregnant women, risk of neurological condition in children

Editor's pick
IDSA press release
5 October 2018